title: [Prostate specific antigen (PSA)/gamma-seminoprotein ratio in the cases with PSA levels less than or equal to 10.0 ng/ml].
abstract: Prostate specific antigen (PSA) and gamma-seminoprotein (gamma-Sm) have been revealed to be the same protein and used as tumor markers for prostate cancer (CaP). However, it seems impossible to detect prostate cancer in the cases with PSA levels of 10.0 ng/ml or less. We now report on PSA/gamma-Sm ratio in the cases with PSA levels of 10.0 ng/ml or less, and on the relation between PSA and gamma-Sm in those cases. Serum samples were obtained from the patients with no cancer (NC) (n = 118) and CaP (n = 39). In the cases with PSA ranging from 4.1 to 10.0 ng/ml, gamma-Sm levels in the patient with CaP were significantly lower than in those with NC (3.744 +/- 2.481 (mean +/- SD, n = 27) VS. 7.573 +/- 4.182 (n = 41), p < 0.0001) though PSA levels in both groups were not significantly different, and consequently, PSA/gamma-Sm ratio in the patients with CaP were significantly higher than in those with NC (2.181 +/- 0.802 VS. 1.095 +/- 0.804, p < 0.0001). In the cases with PSA levels of 4.0 ng/ml or less, gamma-Sm levels in the patient with CaP were significantly lower than in those with NC (1.600 +/- 0.705 (n = 12) VS. 3.243 +/- 2.456 (n = 77), p = 0.0064), while PSA levels in the patients with CaP were not significantly different from those in the patients with NC, and consequently, PSA/gamma-Sm ratio in the patients with CaP were significantly higher than in those with NC (1.762 +/- 0.544 VS. 0.808 +/- 0.330, p < 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Urology, Sappor City General Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Demura
authors.forename: I
authors.initials: I
authors.lastname: Ohyama
authors.forename: M
authors.initials: M
authors.lastname: Togashi
authors.forename: N
authors.initials: N
authors.lastname: Ohashi
authors.forename: T
authors.initials: T
authors.lastname: Chikaraishi
authors.forename: T
authors.initials: T
authors.lastname: Hirano
authors.forename: T
authors.initials: T
authors.lastname: Koyanagi
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000601:surgery; D029584:Prostatic Secretory Proteins; D011506:Proteins / Q000032:analysis*; D011863:Radioimmunoassay; D011933:Reagent Kits, Diagnostic; D029589:Seminal Plasma Proteins; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D029584:Prostatic Secretory Proteins; D011506:Proteins; D011933:Reagent Kits, Diagnostic; D029589:Seminal Plasma Proteins; C043076:beta-microseminoprotein; D017430:Prostate-Specific Antigen